Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
0(0%)
Results Posted
70%(7 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_3
1
9%
Ph phase_1
4
36%
Ph phase_2
6
55%

Phase Distribution

4

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
4(36.4%)
Phase 2Efficacy & side effects
6(54.5%)
Phase 3Large-scale testing
1(9.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.9%

10 of 11 finished

Non-Completion Rate

9.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(10)
Terminated(1)

Detailed Status

Completed10
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
90.9%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (36.4%)
Phase 26 (54.5%)
Phase 31 (9.1%)

Trials by Status

completed1091%
terminated19%

Recent Activity

0 active trials
Showing 5 of 11
terminatedphase_3

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease

NCT05655520
completedphase_1

A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

NCT03770780
completedphase_1

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B

NCT03787758
completedphase_1

A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects

NCT03844906
completedphase_1

A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

NCT03771586
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT05655520Phase 3

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease

Terminated
NCT03770780Phase 1

A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

Completed
NCT03787758Phase 1

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B

Completed
NCT03844906Phase 1

A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects

Completed
NCT03771586Phase 1

A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

Completed
NCT04602624Phase 2

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

Completed
NCT04476017Phase 2

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)

Completed
NCT05107128Phase 2

A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

Completed
NCT05619692Phase 2

A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

Completed
NCT05358821Phase 2

28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

Completed
NCT05318937Phase 2

A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11